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Objective: Although an anti-inflammatory effect of Phaleria macrocarpa (Mahkota Dewa in Indonesian) leaf extract has been reported, the extract 
shows toxicity as the dose increases. Chitosan nanoparticles are known to have transport properties that can enhance the targeting of active 
compounds to tissues at a lower dose. The present study sought to determine whether the extract in chitosan nanoparticles can suppress 
angiogenesis in the colon tissue of mice. 
Methods: We determined the antiangiogenic effect in 6 groups Swiss Webster mice: normal (N) group, negative control (NC) administered drinking 
water containing DSS 2% w/v (7 d) and followed by water without DSS (7 d) in 3 cycles, 12.5 and 25 mg leaf extract of P. macrocarpa/mouse (EPM 
12.5 and EPM 25) groups, and 6.25 and 12.5 mg leaf extract of P. macrocarpa in chitosan nanoparticles/mouse (NPPM 6.25 and NPPM 12.5) groups. 
Hematoxylin and eosin-stained samples was performed to determine the amount of angiogenesis in the colon tissue. 
Results: The angiogenesis in the NPPM 12.5 (p = 0.105) and EPM 25 (p = 0.07) groups was not significantly different to that in the negative control 
group (administered DSS alone). By contrast, angiogenesis in the EPM 12.5 (p = 0.03) and NPPM 6.25 (p = 0.02) groups was significantly less than 
that in the DSS group.  
Conclusion: Angiogenesis in the colon tissue of mice was reduced by the extract with or without chitosan nanoparticles. The greatest reduction was 
found for the 12.5 mg/mouse dose of P. macrocarpa leaf extract in chitosan nanoparticles. 
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INTRODUCTION 
Inflammatory bowel disease (IBD) is a chronic inflammation of the 
digestive tract, which is induced by immunological reactions 
including Crohn’s disease (CD) and ulcerative colitis (UC). Globally, 
there are 10 cases of IBD per 100,000 individuals, with a high 
incidence in Europe and North America. About 2.2–14.3 cases of UC 
per 100,000 individuals and 3.1–14.6 cases of CD per 100,000 
individuals occur each year in North America [1]. In Indonesia, the 
incidence of UC is 0.55 cases per 100,000 individuals, while for CD 
the incidence is 0.33 cases per 100,000 individuals for period 2011–
2012. The incidence is increasing because of the unclear etiology and 
pathophysiology of the disease [2]. 
Persistent proinflammatory cytokine exposure in IBD leads to chronic 
inflammation. This condition is supported by one of the components 
that plays a role in angiogenesis as part of the inflammatory process. 
Angiogenesis is the natural process of new vascular formation to 
supply oxygen, nutrition, and several growth factors, thus maintaining 
the inflammation. Over time, chronic inflammation will initiate an 
oncogenic response such as mutation and epigenetic changes in the 
digestive tract, especially in the colon, and triggers progenitor cancer 
cell formation (cancer-associated colitis) [3, 4]. 
Anti-angiogenesis-based IBD treatment using several types of drugs 
has been developed. Anti-angiogenesis will inhibit the inflammation 
process by suppressing cytokine secretion and proangiogenic factor. 
Bevacizumab is one of most commonly used anti-angiogenic agents 
used with a high success rate. However, bevacizumab is known to 
cause serious side effects, such as intestinal perforation, impaired 
wound healing, and bleeding. Moreover, its high cost is a 
consideration for researchers attempting to discover alternative 
treatments that are not only safe but also affordable [4, 5]. 
The use of naturally occurring ingredients as anti-angiogenesis 
drugs has been studied extensively. Suprapti et al. [6] tested the 
effectiveness of Mahkota Dewa (Phaleria macrocarpa L.) leaf extract 
as an anti-inflammatory agent. Active compounds from the extract 
include kaempferol, quercetin, and phalerin, which have anti-
inflammatory and antiangiogenic effects, suggesting the extract as a 
potential candidate for IBD therapy. However, high doses of the 
extract were found to be toxic in animals [6]. Therefore, we sought 
to determine whether loading the extract in chitosan nanoparticles 
could facilitate better diffusion of the active compound to specific 
tissues to achieve antiangiogenic therapeutic effects with a lower 
extract dose than by using the extract alone [7]. 
MATERIALS AND METHODS 
This experimental study in vivo used a randomized and parallel 
design and was conducted in the Pharmacokinetics Laboratory, 
Pharmacology and Therapeutic Department, Faculty of Medicine, 
Universitas Indonesia (FMUI) in 2018 with approval from the Health 
Research Ethics Committee of FMUI (approval no. 0747/UN2. 
F1/ETIK/2018). 
Animal sample preparation 
Male Swiss Webster mice aged 12 w with an average body weight of 
about 25 g were obtained from the Animal Laboratory of the Center 
for Health Research and Development, Ministry of Health, Jakarta, 
and acclimatized for 7 d before treatment. The mice were housed in 
temperatures below 30 °C under a 12-h light/dark cycle, fed with 
standard feed, and allowed water ad libitum. Based on a power 
calculation, 36 mice were used and were divided into 6 groups that 
received different treatments: no treatment (N), negative control 
(NC) administered drinking water containing DSS 2% w/v (7 d) and 
followed by water without DSS (7 d) in 3 cycles, EPM 25 (DSS 2% 
w/v as described before+25 mg/mouse P. macrocarpa leaf extract 
for 5 w orally, starting on week 2 (day 8), EPM 12.5 (DSS 2% w/v as 
described before+12.5 mg extract/mouse for 5 w orally, starting on 
week 2 (day 8), NPPM 12.5 (DSS 2% w/v as described before+12.5 
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mg extract in chitosan nanoparticles/mouse for 5 w orally, starting 
on week 2 (day 8), NPPM 6.25: DSS 2% w/v as described 
before+6.25 mg extract in chitosan nanoparticles/mouse for 5 w 
orally, starting on week 2 (day 8). 
Tissue preparation 
The mice were killed in week 7 by cervical dislocation. Then, colon 
tissues were harvested and cleaned with water. Colon tissues were 
fixed for 24–48 h with a 10% formalin buffer, dehydrated, cleared 
through a graduated series of increasing concentrations of xylol 
solutions, and infiltrated with paraffin using an automatic tissue 
processor. Subsequently, the colon tissues were embedded into 
paraffin medium in a box cassette and sliced at a thickness of 3–5 
µm using a microtome. The slices were placed in a water bath (40–
50 °C), fixed to glass slides, and dried for 1 h at 40 °C. 
Hematoxylin and eosin staining 
The colon tissue sections fixed on the slides were saturated with 
xylol I and xylol II for 5 min each and then submerged in a graduated 
series of ethanol solutions (90%, 75%, and 70%) for 5 min each. 
Then, the sections were stained by soaking them in a hematoxylin 
solution for 5–10 min, followed by rinsing them under water. 
Subsequently, the sections were dipped into a lithium carbonate 
solution, followed by another water rinse. Then, the sections were 
soaked in an eosin solution for 1-3 min, followed by 3 times 
dehydrating them through a graduated series of alcohol 
concentrations (70%, 75%, and 90%). After that, the sections were 
dipped into xylol I and xylol II solutions for about 5 min each. 
Finally, each section was covered with 1 drop of Ingelan and a cover 
glass. 
Interpretation of hematoxylin and eosin staining 
The histology of colon tissue samples was performed using a Leica 
light microscope and Sigma camera at 400× magnification. 
Examination was conducted in 10 fields of view for each sample. The 
amount of angiogenesis appearance was calculated manually by the 
Image-J program. After that, received data was interpreted to obtain 
a valid data conclusion. 
Data analysis 
The distributions of data were analyzed using a Shapiro-Wilk test, 
followed by a one-way ANOVA with a Tukey post hoc test to 
compare more than 2 groups. Nonhomogeneously distributed data 
were analyzed using a nonparametric Kruskal–Wallis test followed 
by a Mann-Whitney U test. 
RESULTS 
All of the doses of leaf extracts were found to reduce inflammation in 
mouse colon tissue induced by DSS (fig. 1). The amount of 
angiogenesis was significantly less in the EPM 12.5 (p = 0.03) and 
NPPM 6.25 (p = 0.02) groups compared with that in the NC group. By 
contrast, the EPM 25 (p = 0.07) and NPPM 12.5 (p = 0.105) groups 
showed no significant difference in angiogenesis compared with that 
in the NC group. No significant differences were found between the 
treatment groups. The histopathological features of angiogenesis 
appearance was presented in fig. 2. 
 
 
Fig. 1: Mean amount of angiogenesis on mice colon, Note: N = no treatment group; NC = negative control group; EPM 25 = Phaleria 
macrocarpa leaf extract dose 25 mg/mouse; EPM 12.5 = 12.5 mg extract/mouse; NPPM 12.5 = 12.5 mg extract in chitosan 
nanoparticles/mouse; NPPM 6.25 = 6.25 mg extract in chitosan nanoparticles; * = significant difference to NC group 
 
 
Fig. 2: Mice colon tissue after hematoxylin and eosin staining (400× magnification), Note: N = no treatment group; NC = negative control 
group; EPM 25 = Phaleria macrocarpa leaf extract dose 25 mg/mouse; EPM 12.5 = 12.5 mg extract/mouse; NPPM 12.5 = 12.5 mg extract in 
chitosan nanoparticles/mouse; NPPM 6.25 = 6.25 mg extract in chitosan nanoparticles; * = significant difference to NC group 
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P. macrocarpa leaf extract contains several flavonoid subtypes, such 
as quercetin, phalerin, and kaempferol which have anti-
inflammatory, especially anti-angiogenesis properties. We used DSS, 
a polyamine dextran, to induce impairment of gastrointestinal 
permeability and colonic mucosal barrier function. This condition 
triggers cell dysfunction and immune system reactions. We used the 
extracts to reduce cell damage and immune responses. The extract is 
toxic at high dosage. Because of the toxicity, we used chitosan 
nanoparticles to carry the leaf extract to increase targeted drug 
delivery so that the efficacy of extract action could be enhanced. 
Histopathology features showed the ability of the extract to suppress 
the amount of angiogenesis induced by DSS in mice colon tissues, 
possibly due to the anti-inflammatory effects of flavonoids, such as 
kaempferol, which can reduce inflammatory reaction by inhibiting of 
NF-κB activity [6]. The description of the inhibition of angiogenesis by 
P. macrocarpa leaf extract can be caused by the effect of P. macrocarpa 
on anti-inflammatory. The effect of P. macrocarpa on inflammation is 
shown by previous studies. This study showed an inhibition of the 
expression of iNOS protein in the cryptic colon epithelial cells induced 
by DSS [8,9]. The incidence of inhibitory effects is also in line with the 
increase in the extract dose of P. macrocarpa. This inhibition can 
prevent the aggregation of proinflammatory cells and cytokines. The 
amount of angiogenesis was found significantly reduced in all of the 
treatment groups, especially the EPM 12.5 and NPPM 6.25 groups. 
CONCLUSION 
Administration of P. macrocarpa leaf extract directly or carried by 
chitosan nanoparticles has the same ability to reduce the amount of 
angiogenesis in the inflammation reaction induced by DSS in mouse 
colon. EPM 12.5 and NPPM 6.25 groups showed significant reduction 
compared with that in the NC group. 
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